These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8415521)

  • 1. [Glurenorm in the treatment of patients with non-insulin-dependent diabetes mellitus with diseases of the liver and bile ducts].
    Balabolkin MI; Nedosugova LV
    Probl Endokrinol (Mosk); 1993; 39(4):16-8. PubMed ID: 8415521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of glurenorm in patients with non-insulin-dependent diabetes mellitus and liver diseases].
    Dedov II; Demidova IIu; Pisklakov SV; Antokhin EA
    Probl Endokrinol (Mosk); 1993; 39(3):6-8. PubMed ID: 8058688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus].
    Degtiareva II; Lodianaia EV; Opanasiuk ND; Palladina OL
    Lik Sprava; 1995; (7-8):84-7. PubMed ID: 8846383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of glurenorm on plasma glucose and lipids in patients with type 2 diabetes mellitus.
    Chou SC; Chen KW; Huang CC; Lin KD; Hwang JS; Lin JD
    Chang Gung Med J; 2000 Aug; 23(8):480-4. PubMed ID: 11039250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of sugar-reducing therapy on renal function in patients with type II diabetes mellitus].
    Mazurov VI; Novik AA; Nagibovich OA; Romashevskiĭ BV; Guliaeva IV; Kurganova TA
    Klin Med (Mosk); 1998; 76(6):38-41. PubMed ID: 9693499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multicenter study with gliquidone in type 2 diabetes mellitus].
    Kreze A; Vozár J; Rázus P; Lacko A; Málek Z; Putz Z
    Vnitr Lek; 1991; 37(9-10):761-7. PubMed ID: 1771808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comparative evaluation of the effect of glurenorm and sulfonylurea preparations on the intravascular microcirculatory indices in type-II diabetes mellitus].
    Kakhnovskiĭ IM; Koroleva TV; Zakharchenko VN; Larionov SN
    Probl Endokrinol (Mosk); 1993; 39(2):7-9. PubMed ID: 8016059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experience with Glurenorm in type 2 diabetics with renal insufficiency].
    Rybka J; Gregorová A; Zmydlená A
    Vnitr Lek; 1988 Aug; 34(8):786-92. PubMed ID: 3176368
    [No Abstract]   [Full Text] [Related]  

  • 9. [An analysis of the causes of low-efficacy treatment in type-2 diabetes mellitus using sulfonylurea derivatives].
    Gendeleka GF
    Lik Sprava; 1996; (3-4):100-3. PubMed ID: 9035838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined therapy with insulin/gliquidone (Glurenorm) in type 2 diabetes after treatment failure using oral antidiabetic agents].
    Podrouzková B; Krusová D
    Vnitr Lek; 1992 Oct; 38(10):963-7. PubMed ID: 1481374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [40 years of using sulfonylurea derivatives for treatment of diabetes].
    Sieradzki J
    Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Fasching P
    Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
    Ferner RE; Alberti KG
    Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
    [No Abstract]   [Full Text] [Related]  

  • 15. [Glurenorm a new peroral antidiabetic agent belonging to the group of sulfonylurea compounds].
    Grujić M; Rizvanbegović B; Perinović M; Perinović ID
    Med Arh; 1976; 30(2):119-21. PubMed ID: 971371
    [No Abstract]   [Full Text] [Related]  

  • 16. [Increased blood sugar in type 2 diabetes mellitus: what now?].
    Winter T
    Praxis (Bern 1994); 2002 Mar; 91(12):498-502. PubMed ID: 11974431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
    Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
    Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
    [No Abstract]   [Full Text] [Related]  

  • 19. Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease?
    Ann Intern Med; 2012 Nov; 157(9):I-28. PubMed ID: 23128878
    [No Abstract]   [Full Text] [Related]  

  • 20. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
    Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
    Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.